Inclusion Criteria:  Adult subjects ≥ age 18 years Clinical diagnosis of type 1 diabetes for at least one year Using a basal/bolus regimen by injection (MDI therapy) Total daily dose ≥10 units/day Willing to use only aspart (novolog) or lispro (humalog) U-100 insulin with the study pump. A1c ≥ 7.5% and ≤ 11% at screening Not pregnant or planning a pregnancy during the time period of the study. Has current glucagon product to treat severe hypoglycemia (injectable or nasal) at home (will provide prescription if they do not have one) Willingness to follow study procedures and a signed informed consent form  Exclusion Criteria:  Two or more episodes of severe hypoglycemia (needing assistance) in the past 6 months Two or more episodes of diabetic ketoacidosis in the past 6 months Inpatient psychiatric treatment in the past 6 months History of drug abuse (defined as any illicit drug use) or history of alcohol abuse prior to screening or unwillingness to agree to abstain from illicit drugs throughout the study Significant chronic kidney disease or hemodialysis Significant liver disease History of adrenal insufficiency Hypothyroidism or hyperthyroidism that is not appropriately treated Other chronic disease/condition determined by investigator to interfere with participation in the study Use of glucocorticoids, beta blockers or other medications determined by investigator to interfere with study Use of long-acting insulin, inhaled insulin (Afrezza), or use of any non-insulin glucose lowering agents (i.e. SGLT-2 inhibitor) other than Metformin with the study pump Subject is pregnant or lactating or intending to become pregnant before or during participation in this study Investigator judgement that subject would not be able to complete the trial